A perspective on EGFR and Proteasome based targeted therapy for cancer

CONCLUSION: There are numerous strategies that are discussed in these patents to improve the pharmacokinetics and pharmacodynamics of EGFR and proteosome inhibitors. Further, resistance of targeted therapy after long term treatment can be overcome by using various excipients that can be used as a strategy to carry drug in order to overcome resistance. However, there is a need and scope for improving targeted therapeutics for cancer treatment with better fundamentals and characteristics. The widespread research over cancer therapy can create the path for future advancements in therapy with more prominent outcomes.PMID:36089785 | DOI:10.2174/1389450123666220908095121
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Source Type: research